Acute Intoxication with Verapamil

Candell, J; Valle, Vicente; Soler, Montserrat Huguet; Rius, Jorge

doi:10.1378/chest.75.2.200

Cited by 60 publications

(15 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some agents seemed to work for some patients but not others. Of note, there were several reports of patients surviving CCB overdoses with supportive measures alone, both adults (22,33,71,147,148) and children (118,129). In many of these cases, however, the underlying toxicity appears to have been comparatively mild.…”

Section: Other Treatmentsmentioning

confidence: 99%

Calcium Channel Blocker Ingestion: An Evidence-Based Consensus Guideline for Out-of-Hospital Management

Olson

Erdman

Woolf

et al. 2005

Clinical Toxicology

View full text Add to dashboard Cite

Section: Other Treatmentsmentioning

confidence: 99%

Calcium Channel Blocker Ingestion: An Evidence-Based Consensus Guideline for Out-of-Hospital Management

Olson

Erdman

Woolf

et al. 2005

Clinical Toxicology

View full text Add to dashboard Cite

“…9 The calcium channel blocker verapamil was the first agent that was shown to modify MDR in vivo and in vitro, 10 but unfortunately the MDR modulating activity required concentrations that are associated with severe cardiac toxicity in patients. 11 Therefore, a new generation of highly specific and potent Pgp Correspondence: G Lehne, Department of Clinical Pharmacology, Rikshospitalet, The National Hospital of Norway, N-0027 Oslo; Fax: 47 22 11 19 87 Received 28 September 1998; accepted 28 December 1998 inhibitors with less toxic potential have been developed including the non-immunosuppressive cyclosporin SDZ PSC 833, 12 the cyclopeptolide SDZ 280-446, 13 and the cyclopropyldibenzosuberane LY 335979.…”

Section: Introductionmentioning

confidence: 99%

Growth inhibition, cytokinesis failure and apoptosis of multidrug-resistant leukemia cells after treatment with P-glycoprotein inhibitory agents

et al. 1999

View full text Add to dashboard Cite

The multidrug transporter P-glycoprotein (Pgp), which is frequently overexpressed in multidrug resistant leukemia, has many proposed physiological functions including involvement in transmembraneous transport of certain growth-regulating cytokines. Therefore, we studied cell growth of three pairs of drug resistant and sensitive leukemia cell lines (KG1a, K562 and HL60) exposed to three different inhibitors of Pgp. The resistant KG1a and K562 sublines, which expressed high levels of Pgp, responded to low doses of the cyclosporin SDZ PSC 833, the cyclopeptolide SDZ 280-446, and the cyclopropyldibenzosuberane LY335979 with a dose-dependent growth inhibition. In the resistant variants of KG1a and K562 cells the mean half-maximal growth inhibitory doses (GI 50 ) of SDZ PSC 833 were 312 (SE 41) and 414 (SE 50) nM, those of SDZ 280-446 were 685 (SE 51) and 578 (SE 54) nM, and those of LY335979 were 66 (SE 1) and 48 (SE 8) nM, respectively. Exposure to 1 M SDZ PSC 833 resulted in tetraploidization, cytokinesis failure and apoptosis of the KG1a and K562 MDR variants. Conversely, parental cells with no or low levels of Pgp and the non-Pgp resistant variant of HL60 cells were not receptive to these cytotoxic effects. We conclude that inhibition of Pgp may exercise selective cytotoxicity in Pgp-rich leukemia cells indicating a possible therapeutic target in multiresistant leukemia.

show abstract

“…Combination of anticancer drugs with Pgp inhibitors can improve their therapeutic impact [14]. Verapamil was the first agent that was shown to modify MDR in vivo and in vitro [33], but unfortunately the MDR modulating activity required concentrations that are associated with severe cardiac toxicity in patients [37,38]. However, verapamil is still a valuable tool for MDR experiments in vitro and in cellulo.…”

Section: Discussionmentioning

confidence: 99%